Published summary: 2026-03-07
Where the evidence converges
Comprehensive review found synthetic cannabinoids are 2-100x more potent than THC, producing severe adverse effects including psychosis, kidney failure, and cardiac events
Moderate evidence · 5 studies
Based on limited number of strong-evidence studies.
Illinois outbreak linked synthetic cannabinoids contaminated with rat poison (brodifacoum) to 174 severe bleeding cases and 5 deaths in 2018
Moderate evidence · 5 studies
Based on limited number of strong-evidence studies.
Where questions remain
Analysis of 140+ herbal incense products from 2008-2009 showed manufacturers rapidly switched synthetic cannabinoid ingredients in response to German bans, making contents unpredictable for consumers
Moderate evidence · 27 studies
German market may not reflect products in other countries. Analytical methods may not have detected all possible adulterants. The study could not assess health consequences of the identified compounds
Swedish monitoring detected over 50 different new psychoactive substances in emergency patients, predominantly young males, with synthetic cannabinoids among many diverse classes
Moderate evidence · 27 studies
Emergency department presentations represent the most severe outcomes and do not capture the full spectrum of NPS use. Multiple drug intoxications complicated attribution of effects to individual subs
Review found synthetic cannabinoids are full CB1 agonists with higher potency than THC (a partial agonist), explaining their increased potential for adverse reactions and toxicity
Moderate evidence · 27 studies
The rapidly evolving landscape of synthetic cannabinoids means the review may not cover all compounds in circulation. In vivo behavioral studies did not fully differentiate between partial and full ag
A clinical review documented the rise of synthetic cannabinoids and other designer drugs, noting unpredictable toxicity, psychosis risk, and evasion of standard drug tests
Moderate evidence · 27 studies
This was a clinical overview rather than a systematic review. It did not provide detailed epidemiological data or head-to-head comparisons of harm profiles. The rapidly changing nature of synthetic dr
Research gaps
- Only 4 randomized controlled trials exist out of 180 studies — most evidence is observational or from reviews.
- No meta-analyses have been published on this specific topic, limiting the ability to draw pooled quantitative conclusions.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Synthetic Cannabinoids Cause Far More Severe Side Effects Than Natural Cannabis
Synthetic cannabinoids are often marketed as legal alternatives to cannabis, but their 100-fold higher receptor affinity translates to dramatically more dangerous clinical outcomes. This comprehensive review documents the full spectrum of adverse effects, providing evidence for public health campaig
Synthetic Cannabinoids Carry 4-5 Times Higher Psychosis Risk Than Natural Cannabis
While natural cannabis psychosis risk receives significant attention, synthetic cannabinoids pose a dramatically higher risk that is less well recognized. The identification of "spiceophrenia" as a distinct clinical entity with characteristic visual hallucinations and extreme agitation could improve
Even a moderate dose of synthetic cannabinoid JWH-018 caused psychotic-like symptoms in healthy people
This is one of the few controlled studies of a synthetic cannabinoid in humans, providing direct evidence that even moderate doses produce pronounced psychotomimetic symptoms in otherwise healthy individuals.
Synthetic Cannabinoid JWH-018 Impaired Attention, Memory, and Motor Control
Synthetic cannabinoids are widely available but much less studied than THC. Demonstrating clear cognitive and psychomotor impairment at relatively low doses provides evidence to inform public safety policies around these substances.
Synthetic cannabinoid JWH-018 impairs cognition and triggers dissociation in some users
Synthetic cannabinoids are often marketed as legal alternatives to cannabis but may carry distinct risks. This controlled study documents specific cognitive and psychological effects under laboratory conditions.
An online school program reduced teenagers' intentions to use synthetic cannabis for up to 2 years
Synthetic cannabinoids pose unique dangers because of their unpredictable potency and adverse effects. Finding a scalable, web-based prevention program that reduces intentions to use these substances is valuable, especially given the challenges of keeping prevention content current as new synthetic
How the research developed
2000–2009
1 studies published. Predominantly observational and review studies.
2010–2014
13 studies published. Includes 1 strong-evidence studies.
2015–2019
58 studies published. Includes 2 RCTs.
2020–present
108 studies published. Includes 2 RCTs, 4 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 180 peer-reviewed studies: 4 randomized controlled trials (2%), 38 observational studies (21%), 39 reviews (22%), 31 case studies (17%), 68 other study types (38%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.